NCT01937780|Active Not Recruiting
Anal Cancer Radiotherapy Study
ANCARAD
Anal Cancer Radiotherapy - Prospective Study of Treatment Outcome, Patient-Reported Outcomes, Utility of Imaging and Biomarkers, and Cancer Survivorship
Loading search results
ANCARAD
Anal Cancer Radiotherapy - Prospective Study of Treatment Outcome, Patient-Reported Outcomes, Utility of Imaging and Biomarkers, and Cancer Survivorship
Sponsor study identifier
observational
75
1 country
1
Study Start
October 4, 2013
Actual (reported)Primary Completion
September 2022
Actual (reported)Study Completion
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a prospective study of patients receiving radiotherapy or chemoradiotherapy for anal cancer. Treatment effect in terms of survival and local recurrence will be analyzed. The utility of PET-CT and MRI for radiotherapy and for prediction of treatment effect will be investigated. Molecular and genetic markers in tumor and blood will be analyzed for prognostic and predictive effects. Patient-reported outcomes, such as faecal incontinence, sexual dysfunction and quality of life will be assessed. A structured intervention program for management of late effects will be evaluated. Symptom relief of palliative radiotherapy will be investigated. The main purpose of the study is to increase the knowledge of anal cancer treatment, improve treatment results, and improve anal cancer survivor care.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 28, 2013
Actual (reported)September 10, 2013
Actual (reported)October 4, 2013
Actual (reported)September 2022
Actual (reported)May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Disease-free survival
3 years
Prediction of local recurrence
2 years
Biomarker ability to predict local recurrence rate
5 years
Improvement of faecal incontinence
5 years
Pain relief of palliative radiotherapy
5 years
Tumor regression
5 years
PET and MRI prediction of local tumor control
5 years
To identify biomarkers predictive of treatment response or late effects
5 years
Patients with anal cancer to be treated with radiotherapy or chemoradiotherapy
Oslo University Hospital
Oslo, Norway
Hanekamp BA, Viktil E, Dormagen JB, Klow NE, Brunborg C, Malinen E, Guren MG, Schulz A. Optimal time for MRI response evaluation in squamous cell carcinoma of the anus. BJR Open. 2026 Feb 11;8(1):tzag004. doi: 10.1093/bjro/tzag004. eCollection 2026 Jan.
Tissue and blood specimens
Marianne G Guren, MD, PhD
Oslo University Hospital
First Submitted
August 28, 2013
First Posted
September 10, 2013
Study Start
October 4, 2013
Actual (reported)Primary Completion
September 2022
Actual (reported)Individual Following in Anal Cancer With PET/CT
Shared Decision Making With Anal Cancer Patients on Radiation Dose
Contact the study team to confirm eligibility.
Study Completion
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 20, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: